GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arecor Therapeutics PLC (FRA:6UI) » Definitions » Total Inventories

Arecor Therapeutics (FRA:6UI) Total Inventories : €0.53 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Arecor Therapeutics Total Inventories?

Arecor Therapeutics's total inventories for the quarter that ended in Jun. 2024 was €0.53 Mil. Arecor Therapeutics's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Jun. 2024 was €0.71 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Arecor Therapeutics's Net-Net Working Capital per share for the quarter that ended in Jun. 2024 was €-0.05.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year. Arecor Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2024 was 0.00.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Arecor Therapeutics's Inventory-to-Revenue for the quarter that ended in Jun. 2024 was 0.30.


Arecor Therapeutics Total Inventories Historical Data

The historical data trend for Arecor Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arecor Therapeutics Total Inventories Chart

Arecor Therapeutics Annual Data
Trend May17 May18 May19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial - - - 1.30 0.90

Arecor Therapeutics Semi-Annual Data
May18 May19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.08 1.30 1.82 0.90 0.53

Arecor Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Arecor Therapeutics  (FRA:6UI) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Arecor Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2024 is

Net-Net Working Capital Per Share (Q: Jun. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(3.008+0.75 * 1.921+0.5 * 0.527-6.25
-0-0)/30.627
=-0.05

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Arecor Therapeutics's Days Inventory for the six months ended in Jun. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Jun. 2024 )/Cost of Goods Sold (Q: Jun. 2024 )*Days in Period
=0.711/0*365 / 2
=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Arecor Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Jun. 2024 ) / Average Total Inventories (Q: Jun. 2024 )
=0 / 0.711
=0.00

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Arecor Therapeutics's Inventory to Revenue for the quarter that ended in Jun. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=0.711 / 2.358
=0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Arecor Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of Arecor Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Arecor Therapeutics Business Description

Traded in Other Exchanges
Address
Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, Germany, Italy, the Rest of Europe, the USA, and India, out of which the majority is from the UK.

Arecor Therapeutics Headlines

No Headlines